Copenhagen - Delayed Quote DKK

Novo Nordisk A/S (NOVO-B.CO)

444.30
+15.40
+(3.59%)
At close: May 9 at 4:59:51 PM GMT+2
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
303,141,000
290,403,000
232,261,000
176,954,000
140,800,000
Cost of Revenue
47,496,000
44,522,000
35,765,000
28,448,000
23,658,000
Gross Profit
255,645,000
245,881,000
196,496,000
148,506,000
117,142,000
Operating Expense
120,361,000
117,542,000
93,922,000
73,697,000
58,498,000
Operating Income
135,284,000
128,339,000
102,574,000
74,809,000
58,644,000
Net Non Operating Interest Income Expense
-1,921,000
-91,000
330,000
-320,000
-180,000
Other Income Expense
--
-1,057,000
1,770,000
-5,427,000
616,000
Pretax Income
132,306,000
127,191,000
104,674,000
69,062,000
59,080,000
Tax Provision
27,691,000
26,203,000
20,991,000
13,537,000
11,323,000
Net Income Common Stockholders
104,615,000
100,988,000
83,683,000
55,525,000
47,757,000
Diluted NI Available to Com Stockholders
104,615,000
100,988,000
83,683,000
55,525,000
47,757,000
Basic EPS
23.51
22.67
18.67
12.26
10.39
Diluted EPS
23.48
22.63
18.62
12.22
10.37
Basic Average Shares
4,448,875
4,453,900
4,482,800
4,530,600
4,594,227.99
Diluted Average Shares
4,456,975
4,463,000
4,494,800
4,544,600
4,605,303.76
Total Operating Income as Reported
135,284,000
128,339,000
102,574,000
74,809,000
58,644,000
Total Expenses
167,857,000
162,064,000
129,687,000
102,145,000
82,156,000
Net Income from Continuing & Discontinued Operation
104,615,000
100,988,000
83,683,000
55,525,000
47,757,000
Normalized Income
105,437,333.08
101,813,760
82,333,489
59,736,352
47,239,880
Interest Income
3,117,000
1,838,000
1,069,000
239,000
231,000
Interest Expense
4,749,000
1,640,000
542,000
378,000
289,000
Net Interest Income
-1,921,000
-91,000
330,000
-320,000
-180,000
EBIT
137,055,000
128,831,000
105,216,000
69,440,000
59,369,000
EBITDA
146,516,000
137,376,000
114,629,000
76,802,000
65,394,000
Reconciled Cost of Revenue
47,496,000
44,522,000
35,765,000
28,448,000
23,658,000
Reconciled Depreciation
9,461,000
8,545,000
9,413,000
7,362,000
6,025,000
Net Income from Continuing Operation Net Minority Interest
104,615,000
100,988,000
83,683,000
55,525,000
47,757,000
Total Unusual Items Excluding Goodwill
-1,040,000
-1,040,000
1,689,000
-5,238,000
640,000
Total Unusual Items
-1,040,000
-1,040,000
1,689,000
-5,238,000
640,000
Normalized EBITDA
147,556,000
138,416,000
112,940,000
82,040,000
64,754,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-217,666.92
-214,240
339,489
-1,026,648
122,880
12/31/2021 - 1/6/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LLY Eli Lilly and Company
734.57
-2.25%
 
ROG.SW Roche Holding AG
257.60
-0.88%
 
MRK Merck & Co., Inc.
75.97
-2.16%
 
PFE Pfizer Inc.
22.28
-1.15%
 
AZN AstraZeneca PLC
67.57
+0.40%
 
ABBV AbbVie Inc.
184.60
-0.53%
 
JNJ Johnson & Johnson
154.22
-0.93%
 
BAYN.DE Bayer Aktiengesellschaft
24.05
+2.67%
 
BMY Bristol-Myers Squibb Company
46.45
-0.92%
 
SAN.PA Sanofi
92.92
+1.26%